Answers are grounded in this paper and cite their sources.
In vitro analysis shows a drug based on single-stranded RNA reduces rabies virus titer, suggesting new therapies.
Introduction. Rabies is an infectious disease with absolute mortality. Currently, there are no effective drugs and treatment regimens for people with signs of rabies. The only strategy for post-exposure rabies prevention is vaccination and administration of rabies immunoglobulin. At the same time, the search for new treatment and prevention regimens for the disease remains relevant, which is why the development and study of antiviral drugs effective against the rabies virus is relevant. Objective of the study. To study the antiviral activity of a drug based on single-stranded high-polymer RNA of Sacharomyces cerevisiae, which has previously shown antiviral activity against other pathogens of viral infections. Material and methods. The work investigated the effect of the drug based on single-stranded high-polymer RNA of S. cerevisiae "Amphievovir" on the level of reproduction of the attenuated rabies virus strain "Saratov" on the Vero cell culture model. Results. The studied drug in the concentration range from 10 to 20 μg/ml and added to the cell culture no later than 24 hours after infection reduces the titer of the virus by 24.6 to 36.2% compared to the control group. Adding the drug to the infected cell culture later than 24 hours reduces its antiviral effect. Conclusions. The studied drug based on single-stranded high-polymer RNA of S. cerevisiae has antiviral activity against the rabies virus in vitro. The results allow us to justify further study of post-exposure rabies prophylaxis regimens using drugs based on immunostimulating and immunomodulatory RNA
No takes yet. Share an insight, caveat, or question.
Генералов et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: